Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VG-3927 · 1 trial · 2 indications
To evaluate the safety and tolerability of VG-3927
| Arm | Type | Description |
|---|---|---|
| Single and Multiple Ascending Dose | EXPERIMENTAL | Ascending single doses and multiple doses for healthy volunteers. |
| Placebo | PLACEBO_COMPARATOR | Matching placebo |
| Alzheimer's Disease | EXPERIMENTAL | Single Dose Open-label |
| Name | Type | Description |
|---|---|---|
| VG-3927 | DRUG | Dose Escalation |
| Placebo | DRUG | Dose Escalation |
Inclusion Criteria: * The participant is deemed healthy by the principal investigator, as determined by prestudy medical evaluation * The participant voluntarily agrees to participate in this study and signs an institutional review board approved informed consent Exclusion Criteria: * The partici...
Top 20 of 31 competitors
VG-3927 is an investigational small molecule being developed by Vigil Neuroscience, Inc. for Alzheimer disease. It is designed to target TREM2, a protein involved in microglial function in the brain. VG-3927 has completed a Phase 1 clinical trial and is not approved for any indication.
VG-3927 is being developed as a potential treatment for Alzheimer disease. It is an investigational therapy that has completed Phase 1 testing in healthy adults and patients with Alzheimer disease. It has not been approved by the FDA for Alzheimer disease or any other condition.
VG-3927 targets TREM2, a protein expressed on microglia in the central nervous system. TREM2 is involved in microglial activation and phagocytosis, processes implicated in Alzheimer disease pathology. By targeting TREM2, VG-3927 aims to modulate neuroinflammatory responses associated with the disease.
VG-3927 is being developed by Vigil Neuroscience, Inc., a biotechnology company traded on the Nasdaq under the ticker symbol VIGL. Vigil Neuroscience focuses on developing therapies for neurodegenerative diseases, and VG-3927 is its small molecule candidate targeting TREM2 for Alzheimer disease.
VG-3927 has completed a Phase 1 clinical trial. The trial, NCT06343636, was a randomized, double-blind, placebo-controlled study that enrolled 115 participants, including healthy adults and patients with Alzheimer disease, in the United States and Australia. VG-3927 remains investigational and has not been approved by the FDA.
VG-3927 has been evaluated in one completed Phase 1 clinical trial, NCT06343636, titled "A Phase 1 Study of VG-3927 in Healthy Adults and Patients With Alzheimer's Disease." The trial enrolled 115 participants across the United States and Australia and was randomized, double-blind, and placebo-controlled.